Altimmune Inc
3G0
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
59
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,772.00 | 1.00 | -0.01% |
| CAC 40 | 7,637.74 | 28.17 | -0.37% |
| DAX 40 | 23,800.13 | 109.48 | -0.46% |
| Dow JONES (US) | 44,094.77 | 275.50 | 0.63% |
| FTSE 100 | 8,735.30 | 25.66 | -0.29% |
| HKSE | 24,072.28 | 211.87 | -0.87% |
| NASDAQ | 20,369.73 | 96.27 | 0.47% |
| Nikkei 225 | 39,986.33 | 501.06 | -1.24% |
| NZX 50 Index | 12,734.53 | 131.71 | 1.05% |
| S&P 500 | 6,204.95 | 31.88 | 0.52% |
| S&P/ASX 200 | 8,541.10 | 1.20 | -0.01% |
| SSE Composite Index | 3,444.43 | 20.20 | 0.59% |